Cassava Sciences INC 8-K Filing
Ticker: FLNA · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cassava Sciences INC (ticker: FLNA) to the SEC on Dec 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ge on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market).
How long is this filing?
Cassava Sciences INC's 8-K filing is 2 pages with approximately 514 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 514 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-12-18 17:02:27
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA NASDAQ Capital Market
Filing Documents
- sava20251218_8k.htm (8-K) — 28KB
- 0001437749-25-038313.txt ( ) — 155KB
- sava-20251215.xsd (EX-101.SCH) — 3KB
- sava-20251215_def.xml (EX-101.DEF) — 11KB
- sava-20251215_lab.xml (EX-101.LAB) — 15KB
- sava-20251215_pre.xml (EX-101.PRE) — 11KB
- sava20251218_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. Following previously reported communications with the U.S. Food and Drug Administration ("FDA") regarding Cassava Sciences, Inc.'s ("Cassava" or the "Company") investigational new drug application (IND) and proposed proof-of-concept clinical trial for simufilam in tuberous sclerosis complex ("TSC")-related epilepsy, on December 15, 2025, the Company received a formal letter from FDA confirming that the proposed clinical trial is on full clinical hold subject to the Company providing FDA with additional information, including additional pre-clinical data, and modifying the protocol design. Cassava intends to work expeditiously to address the items identified in the letter, however, the Company no longer expects to initiate a proof-of-concept clinical trial for simufilam in TSC-related epilepsy in the first half of 2026 as previously disclosed. The updated timing for initiation of a clinical trial will depend on the Company's ability to provide the requested information and on satisfactory completion of FDA's review. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. a Delaware corporation Date: December 18, 2025 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer